Life sciences company SkinBioTherapeutics’ placing has raised gross proceeds of £4.5m including a cornerstone investment from equity investor Seneca Partners.
Dr Catherine O’Neill, chief executive of SkinBioTherapeutics, said: “Joining AIM is a significant milestone for SkinBioTherapeutics and will give us the visibility we need amongst the established global players we look to partner with. The funds raised will enable us to progress the SkinBiotix technology platform and to accelerate the clinical development of our main therapeutic candidates. This is an exciting time to be in the microbiome space, especially with regards to skin health. We have an experienced team and board, plus the financial and shareholder support to maximise this opportunity.”
See the article in full at InsiderMedia.com